Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%

MT Newswires Live

05/28

Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.

Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.

The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.

Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.

The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2638654388"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638654388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638654388?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638654388","market":"nz","top_or_hot":-1,"title":"Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.</p><p>Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.</p><p>The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.</p><p>Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.</p><p>The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 12:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.</p><p>Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.</p><p>The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.</p><p>Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.</p><p>The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638654388","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638654388","pubTimestamp":1779943470,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharmaron Beijing  plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0216":"研究试验","03759":"康龙化成"},"translate_title":"康龙化成拟50亿元投资药品制造项目；股价下跌3%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":0.9,"03759":0.9},"content_text":"Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}